Combining an antibiotic drug that targets glutamine with the ketogenic diet helps kill glioblastoma cancer cells, reversing symptoms of the disease and improving survivability in mouse models.
A new study reports a genetically modified poliovirus therapy has been shown to improve long term survival rates in recurrent glioblastoma brain cancer patients. Researchers say the therapy had a three year survival rate for 21 percent of participants in a phase 1 clinical trial, compared to just 4% of patients who received more standard treatments.
Researchers discover a way to adjust the malignancy of glioma brain cancer cells in a newly developed 3D hydrogel. The new material mimics the conditions in the brain.
In a study published in Neuro-Oncology, researchers at Mayo Clinic identify an important association between the naturally occurring enzyme Kallikrein 6, also known as KLK6, and glioblastoma multiforme tumors.
Glioblastoma stem cells' circadian clocks ramp up the cells' metabolism, making them stronger, more resistant to treatment, and able to divide and multiply more rapidly. By targeting the stem cells with a small molecule drug, researchers found mice models lived longer and their tumors shrank.
Trifluoperazine, a dopamine receptor antagonist commonly prescribed for schizophrenia, used in combination with radiation therapy delays the growth of glioblastoma brain tumors and prolongs survival for brain cancer.
Introducing VEGF-C into the cerebrospinal fluid of mouse models of glioblastoma, researchers noted increased levels of T cell response to the cancerous tumors. When combined with immune system checkpoint inhibitors, the VEGF-C treatment significantly extended the life span of the mice with glioblastoma brain cancer.
A new study reveals distinct molecular differences in signatures of glioblastoma brain cancer between men and women. Researchers report current treatments for the brain cancer are more effective in women than in men. The findings could help to tailor treatments aimed at the different sexes and improve survival.
Researchers have developed a new drug that could help prolong the lives of people with glioblastoma brain cancer.
PTEN deficiency drives an increased expression of LOX. LOX attracts macrophages which protect gliobastoma brain cancer cells and provide growth factor support for the tumor, a new mouse study reveals.
Genetics and microenvironment influence the frequency of glioblastoma cells. Researchers provide a new blueprint for glioblastoma, integrating the malignant cell programs, cancer cell plasticity, and modulation by genetic drivers. The findings shed light on why this form of cancer is so hard to treat effectively.